Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03008109

Enrollment

Registered

2017-01-02

Start date

2017-02-28

Completion date

2018-11-30

Last updated

2017-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer, Lung Cancer, Nonsmall Cell

Keywords

EGFR-TKI, Recombinant human endostatin

Brief summary

EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS （progression-free survival） , the OS （ overall survival） is limited extended. This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

Interventions

DRUGEGFR-TK Inhibitor

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Advanced NSCLC,EGFR mutation positive,PS（performance status） 0-2,Patients were required to have one or more measurable lesions

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
progression-free survival	18 month

Contacts

Primary ContactZaiwen Fan, MD

kzzaiwenfan@163.com+86 18610949919

Backup ContactZhaoyuan Shi, Bachelor

szy957@aliyun.com+86 15801570739

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026